Metrigraphics has been acquired by Cirtec Medical Corp.

Metrigraphics, a portfolio company of New England Capital Partners and Clarkston Merchant Partners, has been sold to Cirtec Medical, a portfolio company of 3i Group plc (LSE:III).

Metrigraphics is a leading manufacturer of ultra-high precision, custom micron-scale medical device components for growing markets including continuous glucose monitoring, advanced drug delivery, active medication management and life science instruments.

Cirtec Medical Corp. engages in the outsourced design, engineering, development, and manufacturing of class II and III medical devices. The company develops product platforms for neuromodulation, implantable drug delivery, cardiac rhythm management, ventricular assist devices, and minimally invasive surgical systems. It also provides product development services ranging from concept to commercialization, which include program management, design and development, clinical build and regulatory support, and assembly and manufacturing, as well as flexible product transfer programs to allow relocation or duplication of product manufacturing lines to help expand manufacturing capacity, optimize yields, and reserve capital. The company serves medical device companies that range from large manufacturers to small startups around the world.

One of Oaklins' teams in the USA served as the exclusive financial advisor to Metrigraphics in this transaction.